Want to see ATXI full AI Analyst Report?
Avenue Therapeutics (ATXI) AI Stock Analysis
Top Page
Avenue Therapeutics
(Other OTC:ATXI)
The overall score is low primarily because Avenue Therapeutics shows very weak financial health, with no revenue momentum, persistent losses and ongoing cash burn despite a debt-free balance sheet. Secondary pressure comes from a mildly bearish technical setup, as the stock trades below key moving averages with negative momentum and oversold readings. Valuation metrics, including a negative P/E ratio and lack of dividend yield, provide little current fundamental support, reinforcing a cautious view on the stock.
Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 8,925
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.12
- Revenue Growth
- -100.00%
- EPS Growth
- 72.97%
- Country
- US
- Employees
- 1
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Avenue Therapeutics Business Overview & Revenue Model
Company Description
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product c...
How the Company Makes Money
Avenue Therapeutics’ ability to generate revenue is primarily tied to monetizing its drug-development programs rather than diversified operating businesses. In general, the company can make money through (i) collaboration, licensing, or commercializa...
Avenue Therapeutics Financial Statement Overview
Summary
Financial performance is very weak, with zero trailing revenue, deeply negative margins, persistent operating losses, declining equity and ongoing cash burn, even though the company has no debt.
Income Statement
18Very NegativeBalance Sheet
34NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 1.40M | 0 | 0 | 0 | 0 |
| Gross Profit | -1.40M | 1.40M | 0 | 0 | 0 | 0 |
| EBITDA | -3.06M | -3.29M | -11.70M | 4.05M | -2.44M | 7,000 |
| Net Income | -2.78M | -2.91M | -11.65M | -10.38M | -3.55M | -3.73M |
Balance Sheet | ||||||
| Total Assets | 1.98M | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M |
| Cash, Cash Equivalents and Short-Term Investments | 1.94M | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.41M | 1.10M | 816.00K | 1.20M | 3.58M | 509.00K |
| Stockholders Equity | 569.00K | 1.83M | 2.80M | 1.58M | 3.90M | 3.45M |
Cash Flow | ||||||
| Free Cash Flow | -1.38M | -1.83M | -9.03M | -12.45M | -7.60M | -3.75M |
| Operating Cash Flow | -1.38M | -1.83M | -9.03M | -9.45M | -7.60M | -3.75M |
| Investing Cash Flow | 0 | 0 | 0 | -3.00M | 0 | 0 |
| Financing Cash Flow | 0 | 2.09M | 9.84M | 7.53M | 10.54M | 4.38M |
Avenue Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Positive. The current price of 0.43 is above the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.46, and above the 200-day MA of 0.36, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.64 is Neutral, neither overbought nor oversold. The STOCH value of 35.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXI.
Avenue Therapeutics Risk Analysis
Avenue Therapeutics disclosed 65 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAvenue Therapeutics Peers Comparison
Overall Rating
CALC48Neutral
ADXN47Neutral
ENSC45Neutral
CTXR43Neutral
SKYE43Neutral- ATXI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| CALC | 48Neutral | $9.97M | -0.21 | 3398.40% | ― | ― | 15.37% |
| ADXN | 47Neutral | $3.50M | -0.48 | -172.76% | ― | -45.76% | -3.77% |
| ENSC | 45Neutral | $8.19M | -0.15 | -1532.33% | ― | -39.29% | 27.41% |
| CTXR | 43Neutral | $14.36M | -0.25 | -67.15% | ― | ― | 57.48% |
| SKYE | 43Neutral | $5.67M | -0.13 | -329.08% | ― | ― | -19.07% |
| ATXI | 40Underperform | $1.41M | -0.50 | -155.23% | ― | -100.00% | 72.97% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ATXI | Avenue Therapeutics | 0.43 | -0.36 | -45.88% | |
| ENSC | Ensysce Biosciences, Inc. | 0.42 | -1.73 | -80.42% | |
| CTXR | Citius Pharma | 0.52 | -1.00 | -65.59% | |
| SKYE | Skye Bioscience, Inc. | 1.28 | -10.72 | -89.33% | |
| CALC | Calcimedica, Inc. | 1.46 | -13.49 | -90.23% | |
| ADXN | Addex Therapeutics Ltd (ADR) | 3.09 | -5.62 | -64.52% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 02, 2026